NIH has released four new SBIR/STTR solicitations (first deadline for all solicitations is September 8, 2026): Parent SBIR (Clinical Trial Optional) accepts Phase I, Phase II, Direct-to-Phase II, and Fast-Track SBIR awards Parent STTR (Clinical Trial Optional) accepts Phase I, Phase II, Direct-to-Phase II, and Fast-Track STTR awards SBIR Phase IIB Strategic Breakthrough Award (Clinical Trial Optional) accepts Phase IIB Strategic Breakthrough SBIR awards (for Phase II awardees) SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Clinical Trial Optional) accepts CRP awards (for Phase II awardees) Updated summaries of the research interests, budget waiver topics, and award mechanisms supported by individual Institutes and Centers (ICs) are now housed on the Small Business Funding Considerations and Contacts webpage
The body naturally produces very small amounts of this peptide however, it is available as a synthetic supplement for research use only
While further human studies are needed, its mechanism and safety profile make it an exciting option for those interested in peptide therapy
When administered under medical supervision, BPC-157 and TB-500 peptide therapy is generally well tolerated
By promoting muscle recovery, BPC-157 allows you to maintain consistent performance levels, recover faster between workouts, and reduce the risk of injury during intense activities
